Notably, PHGDH inhibition demonstrates synergistic antileukemic activity when combined with established therapeutic agents, including Rylaze and the nucleoside analog cytarabine, suggesting that serine biosynthetic dependency represents an exploitable metabolic vulnerability in FLT3-mutant AML. The gene discussed is PHGDH; the disease is acute myeloid leukemia.